Summary:
- Researchers have identified a key protein that drives an aggressive subtype of prostate cancer, known as neuroendocrine prostate cancer (NEPC).
- By targeting this protein, called SRRM4, the researchers were able to slow the growth of NEPC tumors in laboratory experiments, suggesting a potential new therapeutic approach for this deadly form of the disease.
- The findings provide important insights into the molecular mechanisms underlying NEPC, which is particularly aggressive and resistant to standard treatments, and could lead to the development of more effective therapies for this challenging cancer subtype.